EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Caregiver perspectives on disease burden and treatment priorities in KCNT1-related disorders

Brad A Bryan, Victor Faria, Kaitlyn Esposito, Danielle Boyce, Sarah Poliquin, Ian Terry, Megan Wright, Amanda Abuhl, Allison Rosenberg, David Bearden, Justin West, Sarah Drislane

Epilepsy & Behavior · 2026

DOI: 10.1016/j.yebeh.2026.111053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsy & Behavior, 2026. Verfasst von Brad A Bryan und 11 weiteren Autor:innen. Beteiligte Einrichtung: KCNT1 Epilepsy Foundation, 32531 N Scottsdale Rd, Ste 105-530, Scottsdale, AZ, USA. Electronic address: brad.bryan@kcnt1epilepsy.org. Hauptthemen laut MEDLINE: Caregivers, Cost of Illness, Epilepsy, Potassium Channels, Sodium-Activated. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pathogenic variants in KCNT1, encoding the sodium-activated potassium channel KNa1.1 (Slack), cause severe developmental and epileptic encephalopathies marked by early-onset, treatment-resistant seizures and profound neurodevelopmental impairment. While clinical and electrophysiological features are well described, systematic caregiver-reported data on treatment effectiveness and family impact are limited. METHODS: The KCNT1 Epilepsy Foundation established an international online caregiver-reported registry. Caregivers of individuals with a clinical and/or genetic diagnosis of a KCNT1-related disorder completed structured surveys between April 2023 and January 2024. Data included demographics, genetic variants, seizure characteristics, treatment history, sleep behaviors, quality of life, and family impact using validated and custom instruments. RESULTS: Data from 62 individuals across 13 countries were analyzed. Seizure onset was early (median: 1 month), with diagnosis occurring shortly thereafter (median: 4 months). Sixteen distinct KCNT1 missense variants were reported across the cohort. Caregivers reported a high treatment burden, with a median of 2.5 concurrent antiseizure therapies. The ketogenic diet, clobazam, phenobarbital, and levetiracetam, and vagus nerve stimulation were perceived as highly beneficial, while many conventional antiseizure medications showed limited benefit or worsening. Profound challenges were reported, particularly in cognitive and physical functioning, along with substantial emotional and practical family burden. Treatment priorities extended beyond seizure control to include communication, overall health, and quality of life, with notable gaps between priorities and perceived effectiveness. CONCLUSIONS: Caregiver-reported data demonstrate severe burden and substantial unmet needs in KCNT1-related disorders, highlighting the importance of patient- and family-centered outcome measures in care and therapeutic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CaregiversCost of IllnessEpilepsyPotassium Channels, Sodium-ActivatedNerve Tissue ProteinsHumansFemaleMaleChildAdultQuality of LifeChild, PreschoolAdolescentInfantYoung AdultMiddle AgedAnticonvulsants

Stichwörter der Autor:innen

Caregiver reported outcomesDevelopmental and epileptic encephalopathyEpilepsyFamily impactKCNT1Quality of life

Substanzen

KCNT1 protein, humanPotassium Channels, Sodium-ActivatedNerve Tissue ProteinsAnticonvulsants

Autor:innen und Institutionen

  • KCNT1 Epilepsy Foundation, 32531 N Scottsdale Rd, Ste 105-530, Scottsdale, AZ, USA. Electronic address: brad.bryan@kcnt1epilepsy.org.
  • KCNT1 Epilepsy Foundation, 32531 N Scottsdale Rd, Ste 105-530, Scottsdale, AZ, USA.
  • Tufts Clinical and Translational Science Institute, 35 Kneeland St, Boston, MA, USA.
  • COMBINEDBrain, 1510 Old Hickory Blvd, Brentwood, TN, USA.
  • Formerly at LunaDNA, 10070 Mesa Rim Road, San Diego, CA, USA; Aretetic Solutions, 2108 N Street #12398, Sacramento, CA, USA.
  • University of Rochester Medical Center, Department of Neurology, 601 Elmwood Ave, Rochester, NY, USA.

Zitieren

APA

Bryan, B. A., Faria, V., Esposito, K., Boyce, D., Poliquin, S., Terry, I., Wright, M., Abuhl, A., Rosenberg, A., Bearden, D., West, J., & Drislane, S. (2026). Caregiver perspectives on disease burden and treatment priorities in KCNT1-related disorders. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2026.111053

Vancouver

Bryan BA, Faria V, Esposito K, Boyce D, Poliquin S, Terry I, et al. Caregiver perspectives on disease burden and treatment priorities in KCNT1-related disorders. Epilepsy & Behavior. 2026. doi:10.1016/j.yebeh.2026.111053

BibTeX
@article{Bryan2026,
  author = {Bryan, Brad A and Faria, Victor and Esposito, Kaitlyn and Boyce, Danielle and Poliquin, Sarah and Terry, Ian and Wright, Megan and Abuhl, Amanda and Rosenberg, Allison and Bearden, David and West, Justin and Drislane, Sarah},
  title = {Caregiver perspectives on disease burden and treatment priorities in KCNT1-related disorders},
  journal = {Epilepsy & Behavior},
  year = {2026},
  doi = {10.1016/j.yebeh.2026.111053}
}
Kostenlos starten →